As discussed in Chapter 2, there is scope for the NHS to play a larger role in monitoring and improving health system performance, through selective purchasing and evaluation of providers. The coverage of services reimbursed by NHS is decided based on health technology assessment, which evaluates affordability and cost efficiency for pharmaceutical goods. The scope of NHS coverage is more limited than in other OECD health systems.